- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01299545
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy (PRINT)
Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy
Study Design & Objectives:
Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with a clinical follow-up between 12 and 14 weeks.
To determine the performances of the RA-INF-Dx blood test intended to aid in the identification of patients with rheumatoid arthritis who are unlikely to show an initial response to infliximab and methotrexate combination therapy evaluated according to EULAR response criteria.
Ancillary study objective:
To constitute a biocollection of samples associated with all clinical and biological data collected at inclusion and at the evaluation visit.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The RA-INF-Dx test is a non invasive in vitro blood test intended to aid in the identification of patients with RA who are unlikely to show an initial response to infliximab and methotrexate combination therapy.
The RA-INF-Dx test is indicated for use in patients:
- 18 years of age or older,
- Eligible for a first line biologic therapy with infliximab. The RA-INF-Dx test is indicated for use by rheumatologists as a biological basis for guiding infliximab treatment prior to its initiation.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Mississauga - Chow, Canada
- Location n°31
-
Ontario, Canada
- Location n°36
-
Rimouski, Canada
- Location n°34
-
Saskatchewan, Canada
- Location n°33
-
Toronto, Canada
- Location n°35
-
-
-
-
-
Amiens, Frankrijk
- Location n°41
-
Bobigny, Frankrijk
- Location n°13
-
Dreux, Frankrijk
- Location n°39
-
Grenoble, Frankrijk
- Location n°14
-
Meaux, Frankrijk
- Location n°40
-
Paris, Frankrijk
- Location n°25
-
Paris (Hop Bichat), Frankrijk
- Location n°37
-
Strasbourg, Frankrijk
- Location n°38
-
-
-
-
-
Budapest, Hongarije
- Location n°6
-
Budapest, Hongarije
- Location n°8
-
Debrecen, Hongarije
- Location n°7
-
Eger, Hongarije
- Location n°10
-
Kistarcsa, Hongarije
- Location n°9
-
-
-
-
-
Messina, Italië
- Location n°15
-
Milano, Italië
- Location n°16
-
Pisa, Italië
- Location n°17
-
-
-
-
-
Kaunas, Litouwen
- Location n°27
-
Klaipeda, Litouwen
- Location n°29
-
Panevezys, Litouwen
- Location n°30
-
Vilnius, Litouwen
- Location n°28
-
-
-
-
-
Bucharest, Roemenië
- Location n° 19
-
Bucharest, Roemenië
- Location n°20
-
Bucharest, Roemenië
- Location n°22
-
Bucharest, Roemenië
- Location n°23
-
Cluj Napoca, Roemenië
- Location n°21
-
Iasi, Roemenië
- Location n°24
-
Iasi, Roemenië
- Location n°26
-
Timisoara, Roemenië
- Location n°18
-
-
-
-
-
Banska Bystrica, Slowakije
- Location n°12
-
Piestany, Slowakije
- Location n°11
-
-
-
-
-
Malaga, Spanje
- Location n°3
-
Oviedo, Spanje
- Location n°5
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
Diagnosis of Rheumatoid Arthritis
Patient with a confirmed Rheumatoid Arthritis according the American College of Rheumatology (ACR) classification criteria.
Disease Activity
Patient with a DAS28 greater than 3.2.
Treatment
- Patient eligible for a first line TNFα blocking agent treatment with infliximab according to the "Summary of Product Characteristics",
- Patient refractory to treatment with at least one classical DMARDs (one of which has to be MTX) prescribed according to the international recommendations, i.e. for at least 12 weeks at the maximal tolerated dose prior to infliximab treatment and with doses which must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy (patients may be included if they have undergone a wash-out period using cholestyramine or equivalent subsequent to leflunomide treatment),
Use of oral steroids (≤ 10mg/day of prednisone or equivalent dose of another molecule) and/or NSAIDs will be permitted; doses must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy,
Other criteria
- Patient (male or female) at 18 years of age or older at inclusion,
- Negative β-HCG pregnancy test, when appropriate according to the patient's age and contraceptive method,
- Informed consent signed.
Exclusion Criteria:
- Patient having received previous courses of other biologic therapy (TNF blocking agents, anti-CD20, anti-CTLA4, IL1 blockers, IL6 blockers and other molecules in development),
- Patient non eligible to infliximab therapy according to the "Summary of Product Characteristics",
- Patient with clinically significant, severe and uncontrolled infectious diseases,
- Patient with symptoms of a significant somatic or psychiatric/mental illness,
- Patient with other auto-immune diseases (i.e. Inflammatory Bowel Diseases, Systemic Lupus Erythematosus, vasculitis, uncontrolled asthma, etc...),
- Patient with evidence of cardiac, pulmonary, metabolic, renal, hepatic, gastro-intestinal conditions, which, in the opinion of the investigator, may interfere with the study,
- Pregnancy,
- Patient that is participating in a clinical trial or that participated in a previous one within 10 weeks prior to study entry.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
a single group of patients -200 expected
polyarthrite rhumatoid patients
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To determine the performances of the RA-INF-Dx test to aid in the identification of patients with RA who are unlikely to show an initial response to infliximab and methotrexate combination therapy.
Tijdsspanne: Performed at inclusion : blood samples will be taken before the infliximab infusion.
|
Statistical relationship between the RA-INF-Dx blood test results and the non-response (evaluated according to EULAR criteria) to infliximab and methotrexate combination therapy will be analyzed.
|
Performed at inclusion : blood samples will be taken before the infliximab infusion.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Non-response to infliximab and methotrexate combination therapy based on American College of Rheumatology (ACR) criteria
Tijdsspanne: at the time of the first response evaluation (between the 12th and the 14th week)
|
A statistical analysis will be performed in order to evaluate the predictive performances of the test validated in the study primary objective in relation to the non-response to infliximab and methotrexate combination therapy evaluated according to ACR criteria.
|
at the time of the first response evaluation (between the 12th and the 14th week)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Sara MARSAL, MD, University Hospital Val d'Hebron (Barcelona, Spain)
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2010-A01046-33
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Reumatoïde artritis
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang...Werving
-
Texas Tech University Health Sciences Center, El...Beëindigd
-
Nantes University HospitalVoltooidSeptische arthritisFrankrijk
-
wangxiaodongVoltooid
-
Second Affiliated Hospital, School of Medicine,...VoltooidSeptische arthritisChina
-
Rennes University HospitalVoltooid
-
Assiut UniversityNog niet aan het wervenSeptische arthritis
-
Assiut UniversityNog niet aan het werven
-
Assistance Publique - Hôpitaux de ParisWerving
-
Khoo Teck Puat HospitalOnbekend